康方生物明星药物临床数据引市场震荡,董事长回应:市场反应偏离本质 顶级专家认为解读需更谨慎

每日经济新闻
28 Apr

每经记者 金喆 每经编辑 杨夏4月28日上午的沟通会稍晚了几分钟,康方生物(09926.HK,股价87.2港元,市值783亿港元)董事长夏瑜说话的时候嗓音略带沙哑,每说几句话就会被几声克制不住的咳嗽打断。“可能这两天大家很多人都在忙着突击统计学方面的知识,去年因为我们的临床数据带动了行业理解PFS(中位无进展生存期)与HR值(风险比,主要用于生存分析)的关系,今年又进阶到OS(总生存期)与α...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10